Physician profile
James Carter
NPI 1336143239
$1,744.19
in general payments reported to CMS, 2019-2025
11 companies · $541 in 2025
The $541 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $82.23 · 2021: $145 · 2022: $209 · 2023: $167 · 2024: $127 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $583.05 | 2019-2025 | Penmenvy, Bexsero, Pediarix |
| Pfizer INC. | $410.49 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $217.07 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $201.93 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $166.65 | 2025 | Zoryve |
| Sobi, INC | $53.71 | 2019-2023 | |
| Hologic Sales and Service, LLC | $42.86 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $29.03 | 2024 | Flumist Quadrivalent |
| Lundbeck LLC | $16.29 | 2025 | Rexulti |
| Shire North American Group INC | $15.54 | 2019 | |
| Medline Industries Lp | $7.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.